IN8bio Presents Preclinical Data Showing Non-Signaling CAR Platform Targets Cancer Cells While Preserving Healthy Tissue
~ Next-generation gamma-delta T cell CAR technology targets tumors while sparing healthy tissue. ~ Greater than 15x difference in killing between tumor cells and healthy B cells with the non-signaling gamma-delta CAR-T platform (nsCAR) utilizing the validated target of CD19 as proof-of-concept. ~ Leveraging the unique properties of gamma-delta T cells supports the potential to broaden the utilization of CAR technology for previously “undruggable” solid- and liquid-tumor targets.
To create an account please click on this link.
If you already have an account, please log in here.